James Hanna, MD
Internal Medicine · Pontiac, MINPI 1962818583
Payments from drug & device makers
Across 84 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$304
- Travere Therapeutics, Inc.$190
- AstraZeneca$145
- Novartis$126
- Boehringer Ingelheim$126
- Novo Nordisk$110
- plus $584 from 18 others
What the payments were for
- Food & beverage$1,50795%
- Education$775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 16 | $304 |
| Travere Therapeutics, Inc. | 16 | $190 |
| AstraZeneca | 4 | $145 |
| Novartis | 6 | $126 |
| Boehringer Ingelheim | 7 | $126 |
| Novo Nordisk | 5 | $110 |
| ANI Pharmaceuticals, Inc. | 4 | $97 |
| Calliditas Therapeutics US Inc. | 3 | $80 |
| OPKO Pharmaceuticals, LLC | 4 | $77 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Amgen | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Akebia Therapeutics Inc | 1 | $14 |
| AbbVie | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Pfizer | 1 | $12 |
How this compares
$1,585 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,959 |
| Nifedipine ErNifedipine | 19 | $754 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 11 | $525 |
| Amlodipine Besylate | 34 | $435 |
| Losartan Potassium | 26 | $310 |
| Atorvastatin Calcium | 25 | $256 |
| Lisinopril | 19 | $175 |
| Carvedilol | 12 | $102 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Pontiac
- Tina AbrahamPontiac$834K
- Dipam ShahPontiac$198K
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.